First Header Logo Second Header Logo

Yanjun Hou

Concepts (135)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
11
2022
765
4.110
Why?
Receptor, erbB-2
7
2022
65
2.850
Why?
Carcinoma, Ductal, Breast
3
2019
30
1.760
Why?
Carcinoma, Lobular
3
2019
12
1.760
Why?
Breast
4
2017
68
1.330
Why?
Immunohistochemistry
3
2017
538
1.160
Why?
Fibrocystic Breast Disease
2
2016
3
1.090
Why?
Carcinoma, Intraductal, Noninfiltrating
2
2016
21
1.070
Why?
Neoplasm Recurrence, Local
2
2018
367
1.000
Why?
Cytodiagnosis
3
2020
15
0.900
Why?
Aged, 80 and over
10
2019
3990
0.860
Why?
Neoplasms, Adnexal and Skin Appendage
1
2022
2
0.810
Why?
Adnexal Diseases
1
2022
6
0.800
Why?
Adenoma
1
2022
35
0.780
Why?
Adult
14
2020
9380
0.750
Why?
Middle Aged
15
2020
11839
0.740
Why?
Female
19
2022
20015
0.740
Why?
Molecular Diagnostic Techniques
2
2017
11
0.740
Why?
Aged
14
2020
10314
0.730
Why?
Thyroid Neoplasms
2
2020
33
0.710
Why?
Carcinoma, Neuroendocrine
1
2020
12
0.700
Why?
Mixed Tumor, Mullerian
1
2019
1
0.700
Why?
Adenocarcinoma, Clear Cell
1
2019
2
0.700
Why?
Carcinoma, Endometrioid
1
2019
4
0.690
Why?
Fallopian Tube Neoplasms
1
2019
9
0.690
Why?
Neoplastic Syndromes, Hereditary
1
2019
4
0.650
Why?
Breast Neoplasms, Male
1
2018
11
0.640
Why?
Ovarian Neoplasms
1
2019
96
0.640
Why?
Humans
21
2022
32114
0.600
Why?
Genetic Heterogeneity
1
2017
14
0.600
Why?
CD8-Positive T-Lymphocytes
1
2018
91
0.600
Why?
GATA3 Transcription Factor
1
2017
2
0.590
Why?
Antineoplastic Combined Chemotherapy Protocols
2
2017
458
0.570
Why?
Adenocarcinoma, Mucinous
1
2017
29
0.570
Why?
In Situ Hybridization
1
2017
38
0.570
Why?
Head and Neck Neoplasms
2
2016
130
0.560
Why?
Neoplasms, Second Primary
1
2016
16
0.560
Why?
Carcinoma
2
2016
91
0.550
Why?
Colorectal Neoplasms
1
2019
215
0.550
Why?
Precancerous Conditions
1
2016
27
0.540
Why?
Peritoneal Neoplasms
1
2019
259
0.540
Why?
Sentinel Lymph Node Biopsy
1
2016
70
0.540
Why?
Carcinoma in Situ
1
2016
15
0.530
Why?
Cicatrix
1
2016
39
0.520
Why?
Neoplasm Metastasis
1
2016
220
0.510
Why?
Receptors, Estrogen
3
2022
113
0.490
Why?
Carcinoma, Squamous Cell
1
2016
154
0.490
Why?
Adenocarcinoma
1
2017
308
0.470
Why?
Receptors, Progesterone
3
2019
72
0.440
Why?
Brain Neoplasms
1
2019
638
0.420
Why?
Prognosis
3
2022
1497
0.410
Why?
I-kappa B Kinase
1
2008
8
0.320
Why?
Lymphocytes, Tumor-Infiltrating
2
2019
9
0.320
Why?
Gene Expression Regulation, Developmental
1
2008
69
0.310
Why?
NF-kappa B
1
2008
81
0.310
Why?
Biopsy, Fine-Needle
3
2016
53
0.300
Why?
Neovascularization, Physiologic
1
2008
110
0.300
Why?
Neoadjuvant Therapy
2
2017
67
0.290
Why?
Mastectomy
2
2017
64
0.290
Why?
Hyperplasia
2
2016
41
0.270
Why?
Treatment Outcome
3
2017
3306
0.250
Why?
Signal Transduction
1
2008
682
0.240
Why?
Young Adult
3
2020
2665
0.210
Why?
Follow-Up Studies
2
2019
2265
0.210
Why?
Proteomics
1
2022
94
0.200
Why?
Extraembryonic Membranes
1
2020
4
0.190
Why?
Polyps
1
2020
8
0.190
Why?
Diagnosis, Differential
2
2020
517
0.180
Why?
Uterine Diseases
1
2020
22
0.180
Why?
Colposcopy
1
2020
4
0.180
Why?
Uterine Cervical Dysplasia
1
2020
3
0.180
Why?
Curettage
1
2020
9
0.180
Why?
Vaginal Smears
1
2020
9
0.180
Why?
Paraganglioma
1
2020
5
0.180
Why?
Uterine Cervical Neoplasms
1
2020
36
0.180
Why?
Fallopian Tubes
1
2019
9
0.170
Why?
Peritoneum
1
2019
33
0.170
Why?
Pregnancy Complications
1
2020
105
0.170
Why?
Ovary
1
2019
58
0.170
Why?
Pelvis
1
2019
61
0.170
Why?
Risk Factors
2
2018
3880
0.160
Why?
Neoplasm Invasiveness
2
2017
190
0.160
Why?
Neoplasm Staging
1
2019
447
0.150
Why?
Lymphatic Metastasis
2
2016
166
0.150
Why?
Mastectomy, Segmental
1
2017
27
0.150
Why?
Membrane Transport Proteins
1
2017
35
0.140
Why?
Glycoproteins
1
2017
45
0.140
Why?
Gene Amplification
1
2017
8
0.140
Why?
Genes, erbB-2
1
2017
6
0.140
Why?
Lymph Nodes
1
2017
107
0.140
Why?
Gene Dosage
1
2017
35
0.140
Why?
Genomics
1
2017
85
0.140
Why?
Cyclin-Dependent Kinase Inhibitor p16
1
2016
22
0.140
Why?
Thyroid Nodule
1
2016
7
0.140
Why?
Papillomaviridae
1
2016
22
0.140
Why?
Mammography
1
2016
41
0.140
Why?
Carrier Proteins
1
2017
136
0.140
Why?
Neoplasm Proteins
1
2016
148
0.130
Why?
Gene Expression
1
2016
338
0.120
Why?
Gene Expression Regulation, Neoplastic
1
2016
261
0.120
Why?
Retrospective Studies
2
2020
3510
0.110
Why?
Cohort Studies
1
2017
1817
0.110
Why?
Risk Assessment
1
2017
1429
0.100
Why?
Male
3
2018
19217
0.100
Why?
rho GTP-Binding Proteins
1
2009
10
0.090
Why?
Neoplasms, Squamous Cell
1
2009
9
0.090
Why?
Genes, Lethal
1
2008
1
0.080
Why?
Genes, Reporter
1
2008
40
0.080
Why?
Embryo, Mammalian
1
2008
31
0.080
Why?
Endothelial Cells
1
2008
189
0.070
Why?
Mice, Knockout
1
2008
443
0.070
Why?
Sensitivity and Specificity
2
2020
582
0.070
Why?
Cell Proliferation
1
2008
604
0.070
Why?
Mice
2
2009
2484
0.070
Why?
Alphapapillomavirus
1
2020
10
0.040
Why?
Cervix Uteri
1
2020
28
0.040
Why?
Animals
2
2009
7542
0.040
Why?
Pre-Eclampsia
1
2020
66
0.040
Why?
Placenta
1
2020
74
0.040
Why?
Cesarean Section
1
2020
112
0.040
Why?
Papillomavirus Infections
1
2020
67
0.040
Why?
Genotype
1
2020
733
0.040
Why?
Pregnancy
1
2020
997
0.040
Why?
Gene Expression Profiling
1
2016
322
0.030
Why?
Diabetes Mellitus, Type 2
1
2020
1428
0.020
Why?
Adolescent
1
2020
3568
0.020
Why?
Mice, SCID
1
2009
71
0.020
Why?
Gene Knockdown Techniques
1
2009
77
0.020
Why?
Transfection
1
2009
191
0.020
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2009
263
0.020
Why?
Mice, Nude
1
2009
291
0.020
Why?
Cell Movement
1
2009
169
0.020
Why?
RNA, Messenger
1
2009
508
0.020
Why?
Cell Line, Tumor
1
2009
726
0.020
Why?
Lung Neoplasms
1
2009
414
0.020
Why?
Hou's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (135)
Explore
_
Same Department Expand Description
Explore
_